-
公开(公告)号：US20230271970A1
公开(公告)日：2023-08-31
申请号：US18018012
申请日：2021-07-22
发明人： Yong Qin , Wu Zhong , Fei Xue , Minjie Zhang , Shiyong Fan , Zhibing Zheng , Song Li
IPC分类号： C07D487/04
CPC分类号： C07D487/04
摘要： The present invention relates to the technical field of chemical drug synthesis, and specifically relates to a method for preparing a compound as shown in formula I, comprising: treating the compound as shown in formula VII with an acid to generate the compound as shown in formula I. The method has few synthetic process steps, raw materials which is stable and is easy to prepare, a reaction process which is easy to control, and a high overall yield and purity, and is suitable for industrial preparation.
-
2.发明公开公开(公告)号：US20230271993A1
公开(公告)日：2023-08-31
申请号：US18016062
申请日：2020-07-14
发明人： Xiaoyu Liu , Yong Qin , Wu Zhong , Ruiyuan Cao , Huan He , Zhibing Zheng , Song Li
摘要： The invention relates to a compound represented by general Formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable ester thereof, a pharmaceutically acceptable hydrate thereof or pharmaceutically acceptable solvate thereof and the invention also relates to a pharmaceutical composition comprising the compound, and a preparation method for the compound and a use of the compound.
-
公开(公告)号：US20230219990A1
公开(公告)日：2023-07-13
申请号：US18016172
申请日：2021-07-15
申请人： SICHUAN UNIVERSITY , ACADEMY OF MILITARY MEDICAL SCIENCES , CHENGDU AUPONE PHARMACEUTICAL CO., LTD
发明人： Yong Qin , Wu Zhong , Fei Xue , Xiaoyu Liu , Yu Wang , Xiaohan Zhou , Bo Liu , Ke Wang , Likai Yang , Ruijie Zhou , Yaxin Xiao , Fanglin Xue , Minjie Zhang , Hao Song , Zhibing Zheng , Song Li
摘要： Disclosed is a method for preparing a C-nucleoside compound represented by Formula (III) or salt thereof. The present method has a high reaction yield, is simple to operate, uses a single metal reagent, has stable reaction temperature conditions, does not require frequent changes to the reaction system during the operation process, is suitable for scale-up synthesis, is suitable for large-scale production of Remdesivir, and has low costs.
-
公开(公告)号：US20230293485A1
公开(公告)日：2023-09-21
申请号：US18017471
申请日：2021-07-22
发明人： Ruiyuan Cao , Manli Wang , Wei Li , Lei Zhao , Jingjing Yang , Yuexiang Li , Shiyong Fan , Xinbo Zhou , Dian Xiao , Zhihong Hu , Song Li , Wu Zhong
IPC分类号： A61K31/366 , A61P31/14 , A61K31/365 , A61K31/357
CPC分类号： A61K31/366 , A61P31/14 , A61K31/365 , A61K31/357
摘要： The present invention relates to an application of an artemisinin compound in treatment of coronavirus infection. Specifically, the present invention provides an application of the compound, and a stereoisomer, a pharmaceutically acceptable salt, a solvate or a hydrate thereof in preparation of medicines. The medicines are used for treating diseases or infection caused by coronavirus (preferably SARS-CoV-2), and the compound is selected from one or more of artemisinin, arteether, artemether, artemisia ketone, dihydroartemisinin, artesunate, arteannuin B, and artemisinic acid.
-
公开(公告)号：US20230263811A1
公开(公告)日：2023-08-24
申请号：US18017710
申请日：2021-07-19
发明人： Wu Zhong , Yong Qin , Manli Wang , Ruiyuan Cao , Shiyong Fan , Zhihong Hu , Song Li
CPC分类号： A61K31/658 , A61K45/06 , A61P31/14
摘要： The present application relates to use of cannabidiol in the preparation of a drug for treating coronavirus infections. The present invention specifically relates to cannabidiol, or a geometric isomer, pharmaceutically acceptable salt, solvate or hydrate thereof, or use of a pharmaceutical composition comprising any one or more of the above components in the preparation of a drug for preventing and/or treating diseases or infections caused by a coronavirus.
-
公开(公告)号：US20230218606A1
公开(公告)日：2023-07-13
申请号：US17795471
申请日：2020-06-02
发明人： Wu Zhong , Gengfu Xiao , Zhihong Hu , Manli Wang , Leike Zhang , Ruiyuan Cao , Wei Li , Shiyong Fan , Xinbo Zhou , Song Li
IPC分类号： A61K31/4706 , A61P31/14
CPC分类号： A61K31/4706 , A61P31/14
摘要： Disclosed are hydroxychloroquine or chloroquine, or a geometric isomer thereof, or a pharmaceutically acceptable salt thereof, and/or a solvate thereof, and/or a hydrate thereof, and a pharmaceutical composition containing the above-mentioned compound, and the use thereof in the treatment of diseases or infections caused by SARS-CoV-2.
-
公开(公告)号：US20230071014A1
公开(公告)日：2023-03-09
申请号：US17797048
申请日：2020-07-15
发明人： Wu Zhong , Zhihong Hu , Gengfu Xiao , Ruiyuan Cao , Manli Wang , Leike Zhang , Wei Li , Shiyong Fan , Song Li
IPC分类号： A61K31/427 , A61P31/14
摘要： A use of ritonavir, or a geometric isomer, pharmaceutically acceptable salt, solvate, and/or hydrate thereof, and a pharmaceutical composition containing the above compound in treating a SARS-CoV-2 infections.
-
公开(公告)号：US20220380402A1
公开(公告)日：2022-12-01
申请号：US17621003
申请日：2020-06-22
发明人： Wu Zhong , Min Zhang , Xinbo Zhou , Shiyong Fan , Song Li
IPC分类号： C07H19/167
摘要： The present disclosure provides 6-hydrazinoadenosine represented by the general Formula (I) and its derivatives with A2A adenosine receptor agonist activity, and pharmaceutical compositions containing them. The compound and composition can be used as A2A adenosine receptor agonists and used as medicament.
-
公开(公告)号：US20220363710A1
公开(公告)日：2022-11-17
申请号：US17621099
申请日：2020-06-22
发明人： Wu Zhong , Min Zhang , Xinbo Zhou , Shiyong Fan , Song Li
IPC分类号： C07H19/23
摘要： The present application provides a small-molecule compound, represented by general Formula (I), having A2A adenosine receptor antagonistic activity and a pharmaceutical composition containing same. The compound and composition can be used as A2A adenosine receptor antagonistic agents.
-
公开(公告)号：US11180463B2
公开(公告)日：2021-11-23
申请号：US16382539
申请日：2019-04-12
发明人： Song Li , Wu Zhong , Shuang Cao , Lili Wang , Zhibing Zheng , Junhai Xiao , Xinbo Zhou
IPC分类号： C07D277/22 , A61K31/426 , C07D277/30 , A61K8/49 , A61K31/4422 , A61Q11/00 , A61Q19/08
摘要： The present invention pertains to field of pharmaceutical chemicals, and relates to thiazole inner salt compounds, preparation methods and uses thereof. Specifically, the present invention relates to a compound of Formula I, hydrates or pharmaceutically acceptable salts thereof. The compound of Formula I of the present invention is a potent cross-linking protein cleavage agent, has a stable structure, good physical and chemical properties, and good pharmacological activities, and is suitable for large scale production to obtain samples with stable, controllable and reliable quality, thereby being suitable for pharmaceutical development.
-
-
-
-
-
-
-
-
-
搜索结果
51 条记录 (耗时 0.028 秒)
